Document:

FEE AGREEMENT

Between  SanguiBioTech  AG,  Alfred  Herrhausen  Str.  44 (FEZ), D-58455 Witten,

                                       and

Ms. Dr. Sieglinde Borchert, resident in Sch neberger Str. 15, D-37085 G ttingen.

The  contracting  parties  conclude  the  following  Fee  Agreement:

1.     From  1  June  1998  on,  Ms.  Dr.  Borchert  will work as an independent
freelance  collaborator  and  project  co-ordinator  for  SanguiBioTech  AG.
2.     Ms.  Dr.  Borchert  will  work  on  the  projects as freely determined by
herself.  As for the rest, time and duration of her working hours are subject to
her  sole absolute discretion. In making such determination, she shall take into
account  the  organizational  and  operational processes without, however, being
bound by them. Neither will she be integrated into the operations or operational
processes.
3.     Ms.  Dr.  Borchert  shall  be paid an initial monthly flat-rate fee of DM
6,670.00  plus legal VAT, if applicable. The fee shall be due and payable at the
end  of  every  month.
     Any  expenses  possibly incurred by Ms. Dr. Borchert in connection with her
activities  (see  Item  1)  shall  be  separately  accounted  for.
     It  is  understood  by  the  contracting  parties  that  there is no social
security  obligation  with regard to Ms. Dr. Borchert who will herself take care
of  health  insurance  and  provisions  for  old  age.
     With  regard to taxation, Ms. Dr. Borchert is to be treated as a freelance.
Therefore,  no  wage  tax  will  be  paid  for  her.
4.     Ms.  Dr. Borchert shall be free in determining any off-duty periods (such
as  holiday,  further  training,  congresses).  For  periods  of  absence due to
illness,  she  will  effect  an  appropriate  insurance  (e.g.  daily  benefit
insurance).
5.     Ms.  Dr.  Borchert  declares that she does not suffer from any contagious
disease  and  has  not  concealed  any physical or health defects, in particular
chronic  diseases,  as  far  as  known  to  her.

<PAGE>
6.     Ms.  Dr.  Borchert  is  obliged to observe absolute secrecy towards third
parties  with  regard to any and all internal affairs of the business, trade and
business secrets during and after the termination of this Fee Agreement. This in
particular  applies  to  concrete  and special knowledge, modes of procedure and
methods  in connection with the development of the products of SanguiBioTech AG.
7.     SanguiBioTech AG shall be exclusively entitled to the exploitation of any
inventions made during the work under this Fee Agreement. However, SanguiBioTech
AG  shall  not  be  obliged to exploit such invention, but can release it at its
complete  discretion.  If  exploiting  the  invention, SanguiBioTech AG shall be
obliged  to  pay an adequate compensation. The amount of such compensation shall
depend  on  the  value  of  the  invention  according to the exploitation of the
invention  as  compared  to  the  overall  project.
8.     This  Fee  Agreement  can  be terminated by either party upon one month's
notice  with  effect  from  the  end of a month, in conformity with   621 of the
BGB1.
9.     Any  alterations  of  or  additions  to  this  agreement  must be made in
writing. The same applies to a possible waiver of adherence to the written form.
10.     Should any provision of this agreement be invalid, this shall not affect
the  validity  of  its  remaining  parts.  The  contracting parties undertake to
replace  an  invalid  provision,  if  any, by a valid one that comes as close as
possible  to  the  intended  purpose  or  regulation.

Gottingen,  15  June  1998               Mainz,  15.June  1998
/signature/                              /signature/
(Dr.  S.  Borchert)                     (Member  of  the  Managing  Board
                                        of  SanguiBioTech  AG)
________________________
 German  Civil  CodeSERVICE CONTRACT
Between
GlukoMediTech  AG
     Forschungs-  und  Entwicklungszentrum  (FEZ)
     Alfred-Herrhausen-Str.  44
     D-58455  Witten  an  der  Ruhr
represented  by  the Supervisory Board, the latter represented by its President,
Axel  J.  Kutscher,  Frankensteiner  Platz  95,  D-60594  Frankfurt/M.,
                                      - hereinafter referred to as the Company -

and
Mr.  Prof.  Dr.  Dr.  Wolfgang  Barnikol
     Lanzelhohl  66
     D-55128  Mainz
                     - hereinafter referred to as Member of the Managing Board -

                          1 APPOINTMENT, TASKS AND DUTIES

     (1)  The  Member  of the Managing Board is employed with effect from 15 May
1998.
     (2)  According  to the resolution passed by the Supervisory Board on 14 May
1998,  the  Member  of the Managing Board has been appointed with effect from 15
May  1998  for a term of 5 (five) years as a Member of the Managing Board having
sole  power  of  representation  and  being exempted from the restrictions under
181  of  the  BGB.
     (3)  The  Member  of  the  Managing  Board  shall  conduct  the business of
GlukoMediTech  AG,  together  with  the  other members of the Managing Board, in
accordance  with  the  laws, the Articles of Association, the rules of procedure
for  the management of the Company and the resolutions of the Supervisory Board,
taking  into  account  this  Contract.

                      2 ADDITIONAL OCCUPATION AND COMPETITION

     (1)  The  Member  of  the  Managing  Board  shall  use his working capacity
exclusively  for the Company and its affiliated companies. The assumption of any
additional occupation, whether for or without remuneration, of honorary posts in
the  professional  area,  of  posts in supervisory boards or similar mandates is
subject  to  the  prior  written  approval  of  the  Supervisory  Board.
     (2)  During  the  term of this Service Contract, the Member of the Managing
Board  is  prohibited  from  participating  in  any  business  firm  that  is in
competition  with  the  Company or maintains substantial business relations with
the  Company.  A  possession  of shares that does not enable an influence on the
organs  of  such  business  firm  shall  not  be  considered  a  participation.

<PAGE>

     (3)  The  above  does  not  apply  to  activities for or a participation in
affiliated  companies as well as to the activities of the Member of the Managing
Board  as the head of the sector of Clinical Physiology or a comparable activity
at  the  private  university  of  Witten/Herdecke.

                                  3 REMUNERATION

     (1)  The  Member of the Managing Board shall receive an annual remuneration
to  the amount of US$ 28,000 (twenty-eight thousand US Dollars) to be paid in 12
equal  instalments  of  US$  2,000  (two thousand US Dollars) each at the end of
every  month  after  withholding  the  legal  deductions.  Together  with  the
instalments  for  the  months of June and November, respectively, there shall be
paid  another  instalment  to  the amount of US$ 2,000 (two thousand US Dollars)
each.  The  payment shall be transferred in a cashless manner to a national bank
account  to  be  indicated  by  the  Member  of  the  Managing  Board.
     (2)  The  performance  of  any  tasks  for  affiliated  companies  shall be
regarded  as  compensated  by  the  above-mentioned  remuneration,  unless  the
performance  of  such  tasks substantially increases the workload. This does not
apply  to  the  work  of  the Member of the Managing Board for SanguiBioTech AG.
(3)  Half of any earnings from other service contracts or posts performed by the
Member  of  the Managing Board in the interest or on behalf of the Company shall
be  set  off against the remuneration under Item 1 above. This does not apply to
remuneration  for  the  work  for  SanguiBioTech  AG.
     (4)  The  reimbursement  of expenses incurred by the Member of the Managing
Board  in  performing his service activities, including travel and entertainment
expenses, shall be subject to the respectively applicable policy of the Company.

    4 CONTINUED PAYMENT OF REMUNERATION IN CASE OF ILLNESS, ACCIDENT AND DEATH

     (1)  In  case  the  Member  of  the  Managing  Board, without own fault, is
prevented  from  rendering  his  services  due  to incapacity for work caused by
illness, the remuneration under   3 shall continue to be paid during the time of
the  incapacity  for  work, up to a maximum period of 6 months. If the Member of
the  Managing  Board  receives sickness benefit from his health insurance during
the  incapacity  for  work,  it  is  to  be  set  off.
     (2)  If  the  Member  of  the  Managing  Board  dies during the term of the
Service  Contract,  his  wife  and  the  joint  legitimate children as joint and
several  creditors  or  another person to be named by the Member of the Managing
Board  who  lives  in cohabitation with him shall be paid the remuneration under
3  Subsec.  1  for  the  month  of  the  death  and  the three following months.
(3)  The  Company  shall  appropriately  insure the Member of the Managing Board
against  accidents.

<PAGE>

                           5 INDEMNITY AGAINST LIABILITY

     The  Company  shall  indemnify the Member of the Managing Board against any
claims of the Company or a third party for damages or other compensation, unless
caused  by  intention  or  gross negligence of the Member of the Managing Board.

                               6 SERVICE INVENTIONS

     If the Member of the Managing Board makes any inventions during the term of
his  employment,  the regulations of the Act on Employee Inventions, as amended,
including  any  relevant  regulations  issued,  shall  be  applicable.

                                    7  HOLIDAY

     The  Member  of  the  Managing  Board shall be granted annual holiday of 30
working  days  that  can also be taken in parts. The holiday shall be planned in
agreement  with the other members of the Managing Board, taking into account the
Company's  interests.

                                  8 CONTRACT TERM

     (1)  The  Contract  is  concluded for an initial term ending on 31 December
2003 and then shall be extended always for one year, unless terminated by either
party,  observing a notice period of 6 months. The notice of termination must be
delivered  by  registered  letter.
A  termination  by  the  Company  shall be done by resolution of the Supervisory
Board. A termination by the Member of the Managing Board must be declared before
the  Supervisory  Board.
     (2)  This  shall  not  affect  the  right  to  terminate  the  Contract  in
exceptional  cases. A reason for termination without notice by the Company shall
exist  in  particular  when  the Member of the Managing Board is prohibited from
performing  his  activity by court decision or legally valid administrative act.
     (3)  The  appointment  as  a Member of the Managing Board can be revoked by
decision  of  the  Supervisory Board at any time, notwithstanding any claims for
remuneration  and/or damages. Such revocation at the same time is to be regarded
as  a  termination  with  effect  from  the  next  possible  date.
(4)  The  Company can release the Member of the Managing Board from service duty
if  the  Service  Contract  has  been  duly or extraordinarily terminated or the
appointment  as  a  Member  of  the  Managing  Board  has  been  revoked.

<PAGE>

                             9 DUTY TO OBSERVE SECRECY

     (1)  The  Member of the Managing Board is obliged to observe secrecy on all
internal  affairs of the Company and affiliated companies within and outside the
Company.
     (2)  Upon  termination  of the Service Contract and upon his dismissal, the
Member  of the Managing Board must immediately return all documents and business
papers  to  the  Company.  He  must  not  make  any  copies  of  them.

                                10 FINAL PROVISIONS

     (1)  Should any provision of this Contract be or become invalid, this shall
not  affect  the  validity of the remaining provisions. The parties undertake to
agree,  instead of the invalid provision, on a regulation that comes as close as
possible  to  the  economic  meaning  and  purpose  of  the  invalid  provision.
     (2)  There  were  not  made any collateral agreements to this Contract. Any
alterations  of and additions to this Contract must be made in writing. The same
applies  to  a  waiver  of  the  written  form  requirement.
(3)  As  far  as  the  agreement  on a place of jurisdiction is permissible, the
place  of  jurisdiction  for all disputes on or under this Contract shall be the
seat  of  the  Company  in  Mainz.

Witten,  30  June  1998

GlukoMediTech  AG                         Member  of  the  Managing  Board
/signature/                              /signature/
-----------                              -----------
Axel  J.  Kutscher                       Prof.  Dr.  Dr.  Wolfgang  Barnikol
President  of  the  Supervisory  Board

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]